MORE INFORMATION

Thursday, 14 November 2013

Study finds hormonal levels affect endometrial cancer drug efficiency

Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors, a researcher at UCLA’s Jonsson Comprehensive Cancer Center has shown for the first time. The findings could lead to a novel one-two punch therapy to fight endometrial cancers and provide an alternative option for conventional treatments that, particularly in advanced disease, have limited efficacy. Read more here.

Study mentioned: Janzen DM, et al. Low Levels of Circulating Estrogen Sensitize PTEN-null Endometrial Tumors to PARP Inhibition In Vivo. Mol Cancer Ther. 2013 Nov 12. [Epub ahead of print] PMID: 24222661

No comments:

Post a Comment